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To the Editor: Schrier and colleagues evaluated aggressive blood-pressure control with the use of dual blockade of the renin-angiotensin system in patients with ADPKD. The study also has relevance for physicians who initiated the use of such dual blockade in patients after it was reported that such treatment was more effective than single blockade of the renin-angiotensin-aldosterone system in reducing proteinuria. No potential conflict of interest relevant to this letter was reported. 
To the Editor: The HALT-PKD trial showed that in the low-blood-pressure group, as compared with the standard-blood-pressure group, the annual increase in total kidney volume was significantly less (5.6% vs. 6.6% increase per year). However, there was no benefit with regard to preservation of renal function. Blood-pressure goals were ambitious (95/60 to 110/75 mm Hg in the low-blood-pressure-group and 120/70 to 130/80 mm Hg in the standard-blood-pressure group) 1 in these young patients with ADPKD (mean age, 36.6 to 48.7 years). Current treatment guidelines of the European and U.S. Eighth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure do not support the use of such low bloodpressure targets in patients with nonproteinuric or even proteinuric chronic kidney disease, but instead they suggest blood-pressure targets lower than 140/90 mm Hg in all patients. The European Society of Cardiology guidelines support bloodpressure targets lower than 130 mm Hg in patients with chronic kidney disease and overt proteinuria. 2,3 Blood-pressure goals that are as low as those defined by the HALT-PKD trial investigators may be dangerous in elderly patients with chronic kidney disease, presumably because of the high burden of prevalent cardiovascular disease in these patients. Similarly, in a very large cohort study involving 651,749 U.S. veterans with chronic kidney disease, 4 the optimal blood-pressure range was reported to be 130 to 149 mm Hg systolic pressure and 70 to 89 mm Hg diastolic pressure, and mortality increased markedly with blood-pressure levels lower than 120/80 mm Hg.
estimated GFR slopes to evaluate the benefit of therapy. In our study, patients in the low-bloodpressure group, as compared with patients in the standard-blood-pressure group, had a slower increase in total kidney volume (P = 0.006), a greater reduction in the left-ventricular-mass index (P<0.001), and reduced urinary albumin excretion (P<0.001). We also agree that the on-treatment slope of the estimated GFR shows a benefit for the low blood-pressure group (P = 0.05).
In patients with chronic kidney disease such as ADPKD, the degree of proteinuria is a risk factor for cardiovascular complications and a decrease in kidney function. Thus, Wetzels's point is valid in that dual renin-angiotensin blockade may be indicated if it is shown to lower urinary protein excretion significantly more than monotherapy and is safe. Such may be the case in younger patients with ADPKD.
We 
Atenolol versus Losartan in Marfan's Syndrome
To the Editor: Lacro et al. (Nov. 27 issue) 1 report no benefit of losartan, an angiotensinreceptor blocker (ARB), over the beta-blocker atenolol in respect to the rate of aortic-root dilatation in Marfan's syndrome. A possible interpretation of this study might be that ARBs are as effective as beta-blockers in the treatment of patients with Marfan's syndrome. 2 However, such an interpretation assumes that beta-blockers are an effective treatment option.
Beta-blockers are presently considered to be first-line therapy in patients with Marfan's syndrome. However, their benefit is debatable and not supported by robust evidence. Several observational studies and only one clinical trial 3 have evaluated the effectiveness of beta-blockers in patients with Marfan's syndrome, and the results have been conflicting. Two meta-analyses also reached opposing conclusions 4, 5 (Table 1) . Remarkably, no study showed a benefit of betablockers in preventing clinical end points (e.g., death or dissection).
As a reflection of these uncertainties, the 2010 guidelines of the American College of Cardiology Foundation and the American Heart Association recommend the use of beta-blockers, whereas the 2014 guidelines of the European Society of Cardiology do not. If beta-blockers are not truly effective, then the study by Lacro et al. has really shown that ARBs are as effective as a placebo.
